A year when investment became impact

Lori and Ginger at International Fasion Encounter

We will remember 2023 as the year of major impact achieved through the incredible trust and partnership that so many people in Canada have placed in Crohn’s and Colitis Canada for so many years.

The most significant news of the year was the Genetic, Environmental and Microbial (GEM) Project announcement on July 25. The team released a major finding that brings us closer to a cure for Crohn’s disease. After our 15-year investment – that will continue - the GEM team has discovered that the gut bacteria combination of those who develop Crohn’s disease is different from those who remain healthy – years before they develop Crohn’s. Learn more about the GEM discovery.

Another milestone took place on June 1, when we issued our 2023 Impact of Inflammatory Bowel Disease in Canada report. We have published it every five years since 2007 and it is essential resource to understand the evolution of Crohn’s and colitis over time in our country – and the challenges we will face in future. Learn more about the 2023 Impact of Inflammatory Bowel Disease Report.

Another highlight of the year was our participation in the International Fashion Encounter (IFE) fashion show in Toronto that gave seven models with ostomies a chance to walk the runway. Check out the IFE show photos and video.

What a year, we have much to celebrate. In partnership with you, we will continue to invest time, funds and expertise into achieving positive impact for everyone in Canada affected by Crohn’s and colitis.

Thank you for joining us on this journey to find the cures and improve the life of everyone affected by Crohn’s and colitis in Canada,

Lori Radke
President and CEO
Crohn’s and Colitis Canada

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest